Arbutus to present imdusiran and ab-101 data at easl congress 2025

Five abstracts accepted for poster presentations warminster, pa., april 23, 2025 (globe newswire) -- arbutus biopharma corporation (nasdaq: abus) (“arbutus” or the “company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the european association for the study of the liver (easl) congress 2025 taking place may 7 - 10, 2025 in amsterdam, netherlands.
ABUS Ratings Summary
ABUS Quant Ranking